In the News
Patients with IBD who catch COVID-19 have high clot risk, study finds
Infection with SARS-CoV-2 was associated with an eightfold increase in the risk of venous thromboembolism among patients with inflammatory bowel disease (IBD), but the risk was mitigated by chronic anticoagulation, according to a retrospective study.
Guideline recommends multiple drug classes to treat adults with moderate to severe luminal, fistulizing Crohn's disease
A new clinical practice guideline from the American Gastroenterological Association offered recommendations on which drug classes to use for induction and maintenance of remission, as well as some combination therapies.
Systematic review compares over-the-counter treatments for chronic constipation
Polyethylene glycol and senna had good evidence for their use as first-line laxatives, while moderate evidence supported fiber supplements, fruits, stimulant laxatives, and magnesium-based products.
Cost may be common factor in drug nonadherence among patients with chronic liver disease
About 25% of 3,237 respondents with chronic liver disease in the National Health Interview Survey from 2014 through 2018 reported not taking their medications as prescribed due to cost.
MKSAP Quiz: An epigastric burning sensation
A 45-year-old man reports a two-month history of a burning sensation starting in his stomach and radiating into his chest, usually occurring several times per week. He reports no dysphagia or unintentional weight loss and takes no medication. What is the most appropriate next step in management?
Spotlight on early-onset CRC
As colorectal cancer (CRC) incidence increases among younger adults, earlier screening and detection may lead to improved health outcomes, recent studies found.
FDA restricts use of liver disease drug in certain patients
The agency added new warnings to the prescribing information for obeticholic acid, including a contraindication in patients with primary biliary cholangitis and advanced cirrhosis.
In recurrent C difficile infection, oral FMT capsules have a pooled cure rate of 82% (low-quality evidence)
While the findings of a recent study are promising for oral fecal microbiota transplantation (FMT) capsules to treat patients with recurrent Clostridioides difficile infection, more well-designed trials are needed before routine use, an ACP Journal Club commentary noted.